Home › Companies › SPERO THERAPEUTICS INC. › 2023-2024
At SPERO THERAPEUTICS INC.'s 2 shareholder meetings in the 2023-2024 proxy season (held October 5, 2023 and May 29, 2024), 73 asset managers reported how they voted in their SEC Form N-PX filings, covering 456 separate fund positions. Their filings are grouped here into 15 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item of the season, voted at the meeting held October 5, 2023 — To approve by an advisory vote the compensation of the Company's named executive officers, as… — SPERO THERAPEUTICS INC.'s filing reports the proposal as approved, with 95% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: SPERO THERAPEUTICS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on October 10, 2023.
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and SPERO THERAPEUTICS INC.’s Form 8-K, filed October 10, 2023 (Item 5.07 on EDGAR). Page generated November 8, 2026.
Meeting of October 5, 2023: 8 items on SPERO THERAPEUTICS INC.’s Form 8-K, filed October 10, 2023: 3 elected · 5 approved.
Meeting of May 29, 2024: 6 items on SPERO THERAPEUTICS INC.’s Form 8-K, filed June 3, 2024: 3 elected · 3 approved.
None.
Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided
Proxy season: 2023-2024 2025-2026
Explore SPERO THERAPEUTICS INC. in the interactive database Compare manager voting policies
These tallies are SPERO THERAPEUTICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed October 10, 2023 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX. SPERO THERAPEUTICS INC. reported 2 meetings in this season; each is tabulated separately below, with its own filing.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Milind Deshpande, Ph.D. | 18,831,596 | -- | -- | 2,696,363 | 12,586,113 | 87% | Elected | — |
| Elect Director: Ankit Mahadevia, M.D. | 21,412,529 | -- | -- | 115,430 | 12,586,113 | 99.4% | Elected | — |
| Elect Director: Kathleen Tregoning | 20,945,300 | -- | -- | 582,659 | 12,586,113 | 97% | Elected | — |
| 2. Selection of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 | 33,997,793 | 62,995 | 53,284 | -- | 0 | 99.8% | Approved | — |
| 3. Advisory vote of the compensation of the Company’s named executive officers, as described in the Proxy Statement | 20,123,647 | 1,145,027 | 259,285 | -- | 12,586,113 | 95% | Approved | — |
| 5. Amendment to the Company’s Amended and Restated Certificate of Incorporation, as amended, to reflect new Delaware law provisions regarding officer exculpation | 20,915,583 | 578,765 | 33,611 | -- | 12,586,113 | 97% | Approved | — |
| 6. Amendment to the Company’s Amended and Restated Certificate of Incorporation, as amended, to add a federal forum selection clause | 21,336,574 | 168,709 | 22,676 | -- | 12,586,113 | 99.2% | Approved | — |
| 7. Amendment to the 2017 Plan | 19,839,570 | 1,661,568 | 26,821 | -- | 12,586,113 | 92% | Approved | — |
Source: SPERO THERAPEUTICS INC., Form 8-K, filed with the SEC on October 10, 2023 — read the filing on EDGAR.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Scott Jackson | 23,024,499 | -- | -- | 1,712,167 | 12,035,616 | 93% | Elected | — |
| Elect Director: John C. Pottage, Jr., M.D. | 24,467,399 | -- | -- | 269,267 | 12,035,616 | 99% | Elected | — |
| Elect Director: Cynthia Smith | 24,424,540 | -- | -- | 312,126 | 12,035,616 | 99% | Elected | — |
| 2. Selection of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024 | 36,628,785 | 137,585 | 5,912 | -- | 0 | 99.6% | Approved | — |
| 3. Advisory vote of the compensation of the Company’s named executive officers, as described in the Proxy Statement | 23,890,281 | 442,014 | 404,371 | -- | 12,035,616 | 98% | Approved | — |
| 4. Amendment to the 2017 Plan | 22,794,466 | 1,882,600 | 59,600 | -- | 12,035,616 | 92% | Approved | — |
Source: SPERO THERAPEUTICS INC., Form 8-K, filed with the SEC on June 3, 2024 — read the filing on EDGAR.
Each item below shows how the 73 asset managers that disclosed a SPERO THERAPEUTICS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of SPERO THERAPEUTICS INC.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.
Meeting held October 5, 2023.
Combines 3 wordings of this item as funds reported it.
99.4% Majority: yes · of votes cast
Description as filed by funds: To elect three Class III directors to serve until the 2026 Annual Meeting of Stockholders or until their respective successors are elected and qualified: Ankit Mahadevia, MD
SPERO THERAPEUTICS INC.’s own tally for this item (“Elect Director: Ankit Mahadevia, M.D.”): 21,412,529 for, 115,430 withheld, per its Form 8-K filed October 10, 2023 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “The following nominees were reelected to serve on the Company’s board of directors as Class III directors until the Company’s 2026 annual meeting of stockholders, based on the following votes:”
Support: 99.4% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 14 asset managers below reported 1,890,434 for, 11,753 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 1,206,934 | 0 | 0 | 0 | For |
| Fidelity | 345,889 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 134,800 | 0 | 0 | 0 | For |
| BlackRock | 132,165 | 0 | 0 | 0 | For |
| Charles Schwab | 28,565 | 0 | 0 | 0 | For |
| Legg Mason | 24,483 | 0 | 0 | 0 | For |
| Jackson National | 0 | 0 | 0 | 10,003 | Withhold |
| Northern Trust | 9,073 | 0 | 0 | 0 | For |
| Victory Capital | 3,969 | 0 | 0 | 0 | For |
| Equitable | 2,578 | 0 | 0 | 0 | For |
| Dimensional | 0 | 0 | 0 | 1,750 | Withhold |
| American Century | 1,211 | 0 | 0 | 0 | For |
| John Hancock | 623 | 0 | 0 | 0 | For |
| Guggenheim | 144 | 0 | 0 | 0 | For |
Meeting held October 5, 2023.
Combines 3 wordings of this item as funds reported it.
97% Majority: yes · of votes cast
Description as filed by funds: To elect three Class III directors to serve until the 2026 Annual Meeting of Stockholders or until their respective successors are elected and qualified: Kathleen Tregoning
SPERO THERAPEUTICS INC.’s own tally for this item (“Elect Director: Kathleen Tregoning”): 20,945,300 for, 582,659 withheld, per its Form 8-K filed October 10, 2023 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “The following nominees were reelected to serve on the Company’s board of directors as Class III directors until the Company’s 2026 annual meeting of stockholders, based on the following votes:”
Support: 97% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 14 asset managers below reported 1,890,434 for, 11,753 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 1,206,934 | 0 | 0 | 0 | For |
| Fidelity | 345,889 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 134,800 | 0 | 0 | 0 | For |
| BlackRock | 132,165 | 0 | 0 | 0 | For |
| Charles Schwab | 28,565 | 0 | 0 | 0 | For |
| Legg Mason | 24,483 | 0 | 0 | 0 | For |
| Jackson National | 0 | 0 | 0 | 10,003 | Withhold |
| Northern Trust | 9,073 | 0 | 0 | 0 | For |
| Victory Capital | 3,969 | 0 | 0 | 0 | For |
| Equitable | 2,578 | 0 | 0 | 0 | For |
| Dimensional | 0 | 0 | 0 | 1,750 | Withhold |
| American Century | 1,211 | 0 | 0 | 0 | For |
| John Hancock | 623 | 0 | 0 | 0 | For |
| Guggenheim | 144 | 0 | 0 | 0 | For |
Meeting held October 5, 2023.
Combines 3 wordings of this item as funds reported it.
87% Majority: yes · of votes cast
Description as filed by funds: To elect three Class III directors to serve until the 2026 Annual Meeting of Stockholders or until their respective successors are elected and qualified: Milind Deshpande, PhD
SPERO THERAPEUTICS INC.’s own tally for this item (“Elect Director: Milind Deshpande, Ph.D.”): 18,831,596 for, 2,696,363 withheld, per its Form 8-K filed October 10, 2023 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “The following nominees were reelected to serve on the Company’s board of directors as Class III directors until the Company’s 2026 annual meeting of stockholders, based on the following votes:”
Support: 87% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 14 asset managers below reported 1,394,725 for, 507,462 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 1,206,934 | 0 | 0 | 0 | For |
| Fidelity | 0 | 0 | 0 | 345,889 | Withhold |
| BRIDGEWAY FUNDS INC | 0 | 0 | 0 | 134,800 | Withhold |
| BlackRock | 132,165 | 0 | 0 | 0 | For |
| Charles Schwab | 28,565 | 0 | 0 | 0 | For |
| Legg Mason | 24,483 | 0 | 0 | 0 | For |
| Jackson National | 0 | 0 | 0 | 10,003 | Withhold |
| Northern Trust | 0 | 0 | 0 | 9,073 | Withhold |
| Victory Capital | 0 | 0 | 0 | 3,969 | Withhold |
| Equitable | 2,578 | 0 | 0 | 0 | For |
| Dimensional | 0 | 0 | 0 | 1,750 | Withhold |
| American Century | 0 | 0 | 0 | 1,211 | Withhold |
| John Hancock | 0 | 0 | 0 | 623 | Withhold |
| Guggenheim | 0 | 0 | 0 | 144 | Withhold |
Meeting held May 29, 2024.
Combines 2 wordings of this item as funds reported it.
99% Majority: yes · of votes cast
Description as filed by funds: To elect three Class I directors to serve until the Company's 2027 Annual Meeting of Stockholders or until their respective successors are elected and qualified: Cynthia Smith
SPERO THERAPEUTICS INC.’s own tally for this item (“Elect Director: Cynthia Smith”): 24,424,540 for, 312,126 withheld, per its Form 8-K filed June 3, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “The following nominees were reelected to serve on the Company’s board of directors as Class I directors until the Company’s 2027 annual meeting of stockholders, based on the following votes:”
Support: 99% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 12 asset managers below reported 2,537,068 for, 10,003 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 1,776,214 | 0 | 0 | 0 | For |
| Fidelity | 390,460 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 184,800 | 0 | 0 | 0 | For |
| BlackRock | 78,518 | 0 | 0 | 0 | For |
| Nationwide | 60,900 | 0 | 0 | 0 | For |
| Charles Schwab | 28,565 | 0 | 0 | 0 | For |
| Jackson National | 0 | 0 | 0 | 10,003 | Withhold |
| Northern Trust | 9,073 | 0 | 0 | 0 | For |
| Equitable | 6,560 | 0 | 0 | 0 | For |
| American Century | 1,211 | 0 | 0 | 0 | For |
| John Hancock | 623 | 0 | 0 | 0 | For |
| Guggenheim | 144 | 0 | 0 | 0 | For |
Meeting held May 29, 2024.
Combines 2 wordings of this item as funds reported it.
99% Majority: yes · of votes cast
Description as filed by funds: To elect three Class I directors to serve until the Company's 2027 Annual Meeting of Stockholders or until their respective successors are elected and qualified: John C. Pottage, Jr., M.D.
SPERO THERAPEUTICS INC.’s own tally for this item (“Elect Director: John C. Pottage, Jr., M.D.”): 24,467,399 for, 269,267 withheld, per its Form 8-K filed June 3, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “The following nominees were reelected to serve on the Company’s board of directors as Class I directors until the Company’s 2027 annual meeting of stockholders, based on the following votes:”
Support: 99% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 12 asset managers below reported 2,537,068 for, 10,003 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 1,776,214 | 0 | 0 | 0 | For |
| Fidelity | 390,460 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 184,800 | 0 | 0 | 0 | For |
| BlackRock | 78,518 | 0 | 0 | 0 | For |
| Nationwide | 60,900 | 0 | 0 | 0 | For |
| Charles Schwab | 28,565 | 0 | 0 | 0 | For |
| Jackson National | 0 | 0 | 0 | 10,003 | Withhold |
| Northern Trust | 9,073 | 0 | 0 | 0 | For |
| Equitable | 6,560 | 0 | 0 | 0 | For |
| American Century | 1,211 | 0 | 0 | 0 | For |
| John Hancock | 623 | 0 | 0 | 0 | For |
| Guggenheim | 144 | 0 | 0 | 0 | For |
Meeting held May 29, 2024.
Combines 2 wordings of this item as funds reported it.
93% Majority: yes · of votes cast
Description as filed by funds: To elect three Class I directors to serve until the Company's 2027 Annual Meeting of Stockholders or until their respective successors are elected and qualified: Scott Jackson
SPERO THERAPEUTICS INC.’s own tally for this item (“Elect Director: Scott Jackson”): 23,024,499 for, 1,712,167 withheld, per its Form 8-K filed June 3, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “The following nominees were reelected to serve on the Company’s board of directors as Class I directors until the Company’s 2027 annual meeting of stockholders, based on the following votes:”
Support: 93% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 12 asset managers below reported 2,280,317 for, 266,754 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 1,776,214 | 0 | 0 | 0 | For |
| Fidelity | 390,460 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 0 | 0 | 0 | 184,800 | Withhold |
| BlackRock | 78,518 | 0 | 0 | 0 | For |
| Nationwide | 0 | 0 | 0 | 60,900 | Withhold |
| Charles Schwab | 28,565 | 0 | 0 | 0 | For |
| Jackson National | 0 | 0 | 0 | 10,003 | Withhold |
| Northern Trust | 0 | 0 | 0 | 9,073 | Withhold |
| Equitable | 6,560 | 0 | 0 | 0 | For |
| American Century | 0 | 0 | 0 | 1,211 | Withhold |
| John Hancock | 0 | 0 | 0 | 623 | Withhold |
| Guggenheim | 0 | 0 | 0 | 144 | Withhold |
Meeting held October 5, 2023.
Combines 3 wordings of this item as funds reported it.
99.2% Approved · of votes cast
Description as filed by funds: To approve a proposed amendment to the Company's Amended and Restated Certificate of Incorporation, as amended, to add a federal forum selection clause.
SPERO THERAPEUTICS INC.’s own tally for this item (“6. Amendment to the Company’s Amended and Restated Certificate of Incorporation, as amended, to add a federal forum selection clause”): 21,336,574 for, 168,709 against — passed, per its Form 8-K filed October 10, 2023 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The amendment to the Company’s Amended and Restated Certificate of Incorporation, as amended, to add a federal forum selection clause was approved, based on the following votes:”
Support: 99.2% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 14 asset managers below reported 1,873,622 for, 28,565 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 1,206,934 | 0 | 0 | 0 | For |
| Fidelity | 345,889 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 134,800 | 0 | 0 | 0 | For |
| BlackRock | 132,165 | 0 | 0 | 0 | For |
| Charles Schwab | 0 | 28,565 | 0 | 0 | Against |
| Legg Mason | 24,483 | 0 | 0 | 0 | For |
| Jackson National | 10,003 | 0 | 0 | 0 | For |
| Northern Trust | 9,073 | 0 | 0 | 0 | For |
| Victory Capital | 3,969 | 0 | 0 | 0 | For |
| Equitable | 2,578 | 0 | 0 | 0 | For |
| Dimensional | 1,750 | 0 | 0 | 0 | For |
| American Century | 1,211 | 0 | 0 | 0 | For |
| John Hancock | 623 | 0 | 0 | 0 | For |
| Guggenheim | 144 | 0 | 0 | 0 | For |
Meeting held October 5, 2023.
Combines 3 wordings of this item as funds reported it.
97% Approved · of votes cast
Description as filed by funds: To approve a proposed amendment to the Company's Amended and Restated Certificate of Incorporation, as amended, to reflect new Delaware law provisions regarding officer exculpation.
SPERO THERAPEUTICS INC.’s own tally for this item (“5. Amendment to the Company’s Amended and Restated Certificate of Incorporation, as amended, to reflect new Delaware law provisions regarding officer exculpation”): 20,915,583 for, 578,765 against — passed, per its Form 8-K filed October 10, 2023 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The amendment to the Company’s Amended and Restated Certificate of Incorporation, as amended, to reflect new Delaware law provisions regarding officer exculpation was approved, based on the following votes:”
Support: 97% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 14 asset managers below reported 1,873,622 for, 28,565 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 1,206,934 | 0 | 0 | 0 | For |
| Fidelity | 345,889 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 134,800 | 0 | 0 | 0 | For |
| BlackRock | 132,165 | 0 | 0 | 0 | For |
| Charles Schwab | 0 | 28,565 | 0 | 0 | Against |
| Legg Mason | 24,483 | 0 | 0 | 0 | For |
| Jackson National | 10,003 | 0 | 0 | 0 | For |
| Northern Trust | 9,073 | 0 | 0 | 0 | For |
| Victory Capital | 3,969 | 0 | 0 | 0 | For |
| Equitable | 2,578 | 0 | 0 | 0 | For |
| Dimensional | 1,750 | 0 | 0 | 0 | For |
| American Century | 1,211 | 0 | 0 | 0 | For |
| John Hancock | 623 | 0 | 0 | 0 | For |
| Guggenheim | 144 | 0 | 0 | 0 | For |
Meeting held October 5, 2023.
Combines 3 wordings of this item as funds reported it.
92% Approved · of votes cast
Description as filed by funds: To approve an amendment to the Company's 2017 Stock Incentive Plan, as amended, to increase the total number of shares of common stock authorized for issuance thereunder by 2,500,000 shares.
SPERO THERAPEUTICS INC.’s own tally for this item (“7. Amendment to the 2017 Plan”): 19,839,570 for, 1,661,568 against — passed, per its Form 8-K filed October 10, 2023 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The amendment to the 2017 Plan was approved, based on the following votes:”
Support: 92% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 14 asset managers below reported 1,555,087 for, 347,100 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 1,206,934 | 0 | 0 | 0 | For |
| Fidelity | 0 | 345,889 | 0 | 0 | Against |
| BRIDGEWAY FUNDS INC | 134,800 | 0 | 0 | 0 | For |
| BlackRock | 132,165 | 0 | 0 | 0 | For |
| Charles Schwab | 28,565 | 0 | 0 | 0 | For |
| Legg Mason | 24,483 | 0 | 0 | 0 | For |
| Jackson National | 10,003 | 0 | 0 | 0 | For |
| Northern Trust | 9,073 | 0 | 0 | 0 | For |
| Victory Capital | 3,969 | 0 | 0 | 0 | For |
| Equitable | 2,578 | 0 | 0 | 0 | For |
| Dimensional | 1,750 | 0 | 0 | 0 | For |
| American Century | 0 | 1,211 | 0 | 0 | Against |
| John Hancock | 623 | 0 | 0 | 0 | For |
| Guggenheim | 144 | 0 | 0 | 0 | For |
Meeting held May 29, 2024.
Combines 2 wordings of this item as funds reported it.
92% Approved · of votes cast
Description as filed by funds: To approve an amendment to the Company's 2017 Stock Incentive Plan, as amended, to increase the total number of shares of common stock authorized for issuance thereunder by 3,000,000 shares.
SPERO THERAPEUTICS INC.’s own tally for this item (“4. Amendment to the 2017 Plan”): 22,794,466 for, 1,882,600 against — passed, per its Form 8-K filed June 3, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The amendment to the 2017 Plan was approved, based on the following votes:”
Support: 92% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 12 asset managers below reported 2,289,390 for, 257,681 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 1,776,214 | 0 | 0 | 0 | For |
| Fidelity | 390,460 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 0 | 184,800 | 0 | 0 | Against |
| BlackRock | 78,518 | 0 | 0 | 0 | For |
| Nationwide | 0 | 60,900 | 0 | 0 | Against |
| Charles Schwab | 28,565 | 0 | 0 | 0 | For |
| Jackson National | 0 | 10,003 | 0 | 0 | Against |
| Northern Trust | 9,073 | 0 | 0 | 0 | For |
| Equitable | 6,560 | 0 | 0 | 0 | For |
| American Century | 0 | 1,211 | 0 | 0 | Against |
| John Hancock | 0 | 623 | 0 | 0 | Against |
| Guggenheim | 0 | 144 | 0 | 0 | Against |
Meeting held October 5, 2023.
Combines 9 wordings of this item as funds reported it.
95% Approved · of votes cast
Description as filed by funds: To approve by an advisory vote the compensation of the Company's named executive officers, as disclosed in the proxy statement.
SPERO THERAPEUTICS INC.’s own tally for this item (“3. Advisory vote of the compensation of the Company’s named executive officers, as described in the Proxy Statement”): 20,123,647 for, 1,145,027 against — passed, per its Form 8-K filed October 10, 2023 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The advisory vote of the compensation of the Company’s named executive officers, as described in the Proxy Statement, was approved, based on the following votes:”
Support: 95% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 1,206,934 | 0 | 0 | 0 | For |
| Fidelity | 345,889 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 134,800 | 0 | 0 | 0 | For |
| BlackRock | 132,165 | 0 | 0 | 0 | For |
| Charles Schwab | 28,565 | 0 | 0 | 0 | For |
| Legg Mason | 24,483 | 0 | 0 | 0 | For |
| Jackson National | 0 | 10,003 | 0 | 0 | Against |
| Northern Trust | 9,073 | 0 | 0 | 0 | For |
| Victory Capital | 3,969 | 0 | 0 | 0 | For |
| Equitable | 2,578 | 0 | 0 | 0 | For |
| Dimensional | 0 | 1,750 | 0 | 0 | Against |
| American Century | 1,211 | 0 | 0 | 0 | For |
| John Hancock | 623 | 0 | 0 | 0 | For |
| Guggenheim | 144 | 0 | 0 | 0 | For |
Fund voting reports, all 14 managers: 1,890,434 for, 11,753 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Anson Funds Management LP | 1,447,200 | 0 | 0 | 0 | For |
| Atlas Venture Life Science Advisors, LLC | 1,013,438 | 0 | 0 | 0 | For |
| GV Management Company, L.L.C. | 889,979 | 0 | 0 | 0 | For |
| Rock Springs Capital Management LP | 500,412 | 0 | 0 | 0 | For |
| Novo Holdings A/S | 468,902 | 0 | 0 | 0 | For |
| AWM Investment Company, Inc. | 383,400 | 0 | 0 | 0 | For |
| BlackRock | 382,455 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 382,405 | 0 | 0 | 0 | For |
| AMERIPRISE FINANCIAL INC | 0 | 373,086 | 0 | 0 | Against |
| Renaissance | 335,946 | 0 | 0 | 0 | For |
| DAFNA Capital Management LLC | 125,000 | 0 | 0 | 0 | For |
| ACADIAN ASSET MANAGEMENT LLC | 99,938 | 0 | 0 | 0 | For |
| State Street | 59,211 | 0 | 0 | 0 | For |
| Ensign Peak Advisors, Inc | 47,280 | 0 | 0 | 0 | For |
| Two Sigma | 36,712 | 0 | 0 | 0 | For |
| Fisher Asset Management, LLC | 29,200 | 0 | 0 | 0 | For |
| Charles Schwab | 28,565 | 0 | 0 | 0 | For |
| Royce | 24,483 | 0 | 0 | 0 | For |
| MACKENZIE FINANCIAL CORP | 0 | 17,198 | 0 | 0 | Against |
| BOURGEON CAPITAL MANAGEMENT LLC | 0 | 15,100 | 0 | 0 | Against |
| Prudential/PGIM | 0 | 14,200 | 0 | 0 | Against |
| Northern Trust | 10,922 | 0 | 0 | 0 | For |
| Vanguard | 10,162 | 0 | 0 | 0 | For |
| Dimensional | 0 | 10,003 | 0 | 0 | Against |
| Texas Yale Capital Corp. | 10,000 | 0 | 0 | 0 | For |
Institutional-manager reports, all 52 managers: 6,325,781 for, 443,134 against. Showing the 25 largest; every one is in the interactive database (link above).
Meeting held October 5, 2023.
Combines 6 wordings of this item as funds reported it.
100% Fund and manager reports combined; may count the same shares twice · no official result
Description as filed by funds: To approve by an advisory vote the frequency of holding an advisory vote on compensation of the Company's named executive officers.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice). The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 0 | 0 | 0 | 0 | -- |
| Fidelity | 0 | 0 | 0 | 0 | -- |
| BRIDGEWAY FUNDS INC | 0 | 0 | 0 | 0 | -- |
| BlackRock | 0 | 0 | 0 | 0 | -- |
| Charles Schwab | 0 | 0 | 0 | 0 | -- |
| Legg Mason | 0 | 0 | 0 | 0 | -- |
| Jackson National | 0 | 0 | 0 | 0 | -- |
| Northern Trust | 0 | 0 | 0 | 0 | -- |
| Victory Capital | 0 | 0 | 0 | 0 | -- |
| Equitable | 0 | 0 | 0 | 0 | -- |
| Dimensional | 0 | 0 | 0 | 0 | -- |
| American Century | 0 | 0 | 0 | 0 | -- |
| John Hancock | 0 | 0 | 0 | 0 | -- |
| Guggenheim | 0 | 0 | 0 | 0 | -- |
Fund voting reports, all 14 managers: 1,890,434 1 year, 11,753 3 year.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Atlas Venture Life Science Advisors, LLC | 0 | 0 | 0 | 0 | -- |
| GV Management Company, L.L.C. | 0 | 0 | 0 | 0 | -- |
| Rock Springs Capital Management LP | 0 | 0 | 0 | 0 | -- |
| Novo Holdings A/S | 0 | 0 | 0 | 0 | -- |
| BlackRock | 0 | 0 | 0 | 0 | -- |
| GEODE CAPITAL MANAGEMENT, LLC | 0 | 0 | 0 | 0 | -- |
| AMERIPRISE FINANCIAL INC | 0 | 0 | 0 | 0 | -- |
| Renaissance | 0 | 0 | 0 | 0 | -- |
| DAFNA Capital Management LLC | 0 | 0 | 0 | 0 | -- |
| ACADIAN ASSET MANAGEMENT LLC | 0 | 0 | 0 | 0 | -- |
| State Street | 0 | 0 | 0 | 0 | -- |
| Ensign Peak Advisors, Inc | 0 | 0 | 0 | 0 | -- |
| Two Sigma | 0 | 0 | 0 | 0 | -- |
| Fisher Asset Management, LLC | 0 | 0 | 0 | 0 | -- |
| Charles Schwab | 0 | 0 | 0 | 0 | -- |
| Royce | 0 | 0 | 0 | 0 | -- |
| MACKENZIE FINANCIAL CORP | 0 | 0 | 0 | 0 | -- |
| BOURGEON CAPITAL MANAGEMENT LLC | 0 | 0 | 0 | 0 | -- |
| Prudential/PGIM | 0 | 0 | 0 | 0 | -- |
| Northern Trust | 0 | 0 | 0 | 0 | -- |
| Vanguard | 0 | 0 | 0 | 0 | -- |
| Dimensional | 0 | 0 | 0 | 0 | -- |
| Texas Yale Capital Corp. | 0 | 0 | 0 | 0 | -- |
| MELLON INVESTMENTS Corp | 0 | 0 | 0 | 0 | -- |
| Corient Private Wealth LLC | 0 | 0 | 0 | 0 | -- |
Institutional-manager reports, all 49 managers: 409 for, 4,874,866 1 year, 57,583 3 year. Showing the 25 largest; every one is in the interactive database (link above).
Meeting held May 29, 2024.
Combines 5 wordings of this item as funds reported it.
98% Approved · of votes cast
Description as filed by funds: To approve by an advisory vote the compensation of the Company's named executive officers, as disclosed in the proxy statement.
SPERO THERAPEUTICS INC.’s own tally for this item (“3. Advisory vote of the compensation of the Company’s named executive officers, as described in the Proxy Statement”): 23,890,281 for, 442,014 against — passed, per its Form 8-K filed June 3, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The advisory vote of the compensation of the Company’s named executive officers, as described in the Proxy Statement, was approved, based on the following votes:”
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 1,776,214 | 0 | 0 | 0 | For |
| Fidelity | 330,495 | 0 | 0 | 0 | For |
| BlackRock | 78,518 | 0 | 0 | 0 | For |
| Nationwide | 60,900 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 50,000 | 0 | 0 | 0 | For |
| Charles Schwab | 28,565 | 0 | 0 | 0 | For |
| Jackson National | 0 | 10,003 | 0 | 0 | Against |
| Equitable | 6,560 | 0 | 0 | 0 | For |
| American Century | 0 | 1,211 | 0 | 0 | Against |
| John Hancock | 623 | 0 | 0 | 0 | For |
Fund voting reports, all 10 managers: 2,331,875 for, 11,214 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Anson Funds Management LP | 3,750,450 | 0 | 0 | 0 | For |
| GV Management Company, L.L.C. | 889,979 | 0 | 0 | 0 | For |
| Renaissance | 549,944 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 469,441 | 0 | 0 | 0 | For |
| Ensign Peak Advisors, Inc | 374,418 | 0 | 0 | 0 | For |
| BlackRock | 359,524 | 0 | 0 | 0 | For |
| ACADIAN ASSET MANAGEMENT LLC | 344,563 | 0 | 0 | 0 | For |
| State Street | 113,585 | 0 | 0 | 0 | For |
| Northern Trust | 101,886 | 0 | 0 | 0 | For |
| Man Group plc | 83,470 | 0 | 0 | 0 | For |
| BAILARD, INC. | 60,900 | 0 | 0 | 0 | For |
| Citadel | 55,630 | 0 | 0 | 0 | For |
| FERGUSON WELLMAN CAPITAL MANAGEMENT, INC | 40,000 | 0 | 0 | 0 | For |
| Fisher Asset Management, LLC | 30,780 | 0 | 0 | 0 | For |
| Charles Schwab | 28,565 | 0 | 0 | 0 | For |
| MACKENZIE FINANCIAL CORP | 28,442 | 0 | 0 | 0 | For |
| Prudential/PGIM | 12,800 | 0 | 0 | 0 | For |
| Texas Yale Capital Corp. | 10,000 | 0 | 0 | 0 | For |
| Corient Private Wealth LLC | 8,750 | 0 | 0 | 0 | For |
| Point72 | 8,101 | 0 | 0 | 0 | For |
| BOURGEON CAPITAL MANAGEMENT LLC | 7,600 | 0 | 0 | 0 | For |
| Janney Montgomery Scott LLC | 5,000 | 0 | 0 | 0 | For |
| MELLON INVESTMENTS Corp | 0 | 4,179 | 0 | 0 | Against |
| D.A. DAVIDSON & CO. | 2,800 | 0 | 0 | 0 | For |
| Fidelity | 2,200 | 0 | 0 | 0 | For |
Institutional-manager reports, all 37 managers: 7,347,418 for, 5,390 against. Showing the 25 largest; every one is in the interactive database (link above).
Meeting held October 5, 2023.
Combines 3 wordings of this item as funds reported it.
99.8% Approved · of votes cast
Description as filed by funds: To ratify the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023.
SPERO THERAPEUTICS INC.’s own tally for this item (“2. Selection of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023”): 33,997,793 for, 62,995 against — passed, per its Form 8-K filed October 10, 2023 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The selection of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 was ratified, based on the following votes:”
Support: 99.8% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 14 asset managers below reported 1,902,187 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 1,206,934 | 0 | 0 | 0 | For |
| Fidelity | 345,889 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 134,800 | 0 | 0 | 0 | For |
| BlackRock | 132,165 | 0 | 0 | 0 | For |
| Charles Schwab | 28,565 | 0 | 0 | 0 | For |
| Legg Mason | 24,483 | 0 | 0 | 0 | For |
| Jackson National | 10,003 | 0 | 0 | 0 | For |
| Northern Trust | 9,073 | 0 | 0 | 0 | For |
| Victory Capital | 3,969 | 0 | 0 | 0 | For |
| Equitable | 2,578 | 0 | 0 | 0 | For |
| Dimensional | 1,750 | 0 | 0 | 0 | For |
| American Century | 1,211 | 0 | 0 | 0 | For |
| John Hancock | 623 | 0 | 0 | 0 | For |
| Guggenheim | 144 | 0 | 0 | 0 | For |
Meeting held May 29, 2024.
Combines 2 wordings of this item as funds reported it.
99.6% Approved · of votes cast
Description as filed by funds: To ratify the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024.
SPERO THERAPEUTICS INC.’s own tally for this item (“2. Selection of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024”): 36,628,785 for, 137,585 against — passed, per its Form 8-K filed June 3, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The selection of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024 was ratified, based on the following votes:”
Support: 99.6% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 12 asset managers below reported 2,547,071 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 1,776,214 | 0 | 0 | 0 | For |
| Fidelity | 390,460 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 184,800 | 0 | 0 | 0 | For |
| BlackRock | 78,518 | 0 | 0 | 0 | For |
| Nationwide | 60,900 | 0 | 0 | 0 | For |
| Charles Schwab | 28,565 | 0 | 0 | 0 | For |
| Jackson National | 10,003 | 0 | 0 | 0 | For |
| Northern Trust | 9,073 | 0 | 0 | 0 | For |
| Equitable | 6,560 | 0 | 0 | 0 | For |
| American Century | 1,211 | 0 | 0 | 0 | For |
| John Hancock | 623 | 0 | 0 | 0 | For |
| Guggenheim | 144 | 0 | 0 | 0 | For |
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 52,696,289 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 2.29% |
| 2 | Fidelity | 0.66% |
| 3 | BRIDGEWAY FUNDS INC | 0.26% |
| 4 | BlackRock | 0.25% |
| 5 | Charles Schwab | 0.05% |
| 6 | Legg Mason | 0.05% |
| 7 | Jackson National | 0.02% |
| 8 | Northern Trust | 0.02% |
| 9 | Victory Capital | <0.01% |
| 10 | Equitable | <0.01% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Anson Funds Management LP | 2.75% |
| 2 | Atlas Venture Life Science Advisors, LLC | 1.92% |
| 3 | GV Management Company, L.L.C. | 1.69% |
| 4 | Rock Springs Capital Management LP | 0.95% |
| 5 | Novo Holdings A/S | 0.89% |
| 6 | AWM Investment Company, Inc. | 0.73% |
| 7 | BlackRock | 0.73% |
| 8 | GEODE CAPITAL MANAGEMENT, LLC | 0.73% |
| 9 | AMERIPRISE FINANCIAL INC | 0.71% |
| 10 | Renaissance | 0.64% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.
| Holder | % outstanding | Disclosure |
|---|---|---|
| GSK Equity Investments, Limited | 17.44% | DEF14A |
| GSK PLC | 17.44% | 13D |
| Anson Funds Management, LP | 8.16% | DEF14A |
| S | 7.12% | 13G |
| Vanguard Group | 3.78% | 13F |
| Ankit Mahadevia, M.D. | 2.74% | DEF14A |
| Renaissance Technologies | 1.62% | 13F |
| Geode Capital | 0.89% | 13F |
| BlackRock | 0.83% | 13F |
| Timothy Keutzer | 0.57% | DEF14A |
Percentages above are of 52,696,289 shares outstanding, as reported by SPERO THERAPEUTICS INC. on its Form 10-Q dated August 4, 2023 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from SPERO THERAPEUTICS INC.’s 10-Q dated August 4, 2023. This page is a static snapshot rebuilt weekly on November 8, 2026; a live search always shows the current data.
SPERO THERAPEUTICS INC. proxy season coverage: 2023-2024 (this page) · 2025-2026.
proxyvotesnow.com, “SPERO THERAPEUTICS (SPRO) 2023-2024 Annual Meetings: Vote Results”, https://proxyvotesnow.com/company/spero-therapeutics-inc/2024 (version of November 9, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.